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This study has investigated the effect of interrupting nasal continuous positive airway pressure (nCPAP) therapy on 
10 obstructive sleep apnoea (OSA) patients (nine male, one female) (53.6 =t 7.3 years) treated over 2 years. The effect 
of nCPAP interruption was determined by variations in sleep counts and gasometric values during five consecutive 
nights. On the first night, the patient used his habitual nCPAP. On the remaining nights, nasal nCPAP was not 
applied. 
The apnoea-hypopnoea index (AHI) was found to increase significantly in the second night, attaining a similar 
level to that of the basal study (2 years ago). SaO, minimum decreased and PaCO, increased in the second night 
with respect to the first night. 
The interruption of nCPAP therapy in OSA patients treated over a long period of time increases the sleep counts 
and impairs the gasometric parameters. Consequently, any change in nCPAP time therapy must be checked to avoid 
negative effects. 
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Introduction 
Nasal continuous positive airway pressure (nCPAP) is the 
most effective non-surgical treatment for obstructive 
sleep apnoea (OSA) (I). For most patients, nCPAP is 
well tolerated, although adverse side-effects have been 
described. In some patients, prolonged nCPAP treatment 
can lead to impaired quality of life because patients must 
spend part of their lives with an external ventilator (2). To 
obviate these problems, alternatives to continuous nCPAP 
therapy have been proposed. Alternate night nCPAP for 
only part of the night has been applied (3,4). The sleep 
function effects of such interruption of nCPAP treatment 
are poorly understood, and therefore protocol changes raise 
many uncertainties. Hence, the authors studied the effects 
of interrupting nCPAP treatment by observing changes in 
the apnoea-hypopnoea index (AHI) and gas exchange in 10 
OSA patients who had been using nCPAP for 2 years. 
Materials and Methods 
Ten OSA patients (nine male, 1 female) (53.60 f 7.3 years) 
participated in the study. The patients were recruited from 
individuals coming to the authors’ surgery with sleeping 
difficulties, all from the town of Badalona and the area 
served by the authors’ hospital. The main clinical com- 
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plaints of the patients studied were daytime hypersomnia 
(93.8%), loud snoring (96.9%), disturbed sleep (89.1%), 
morning headaches (48.4%) and bed wetting (20.4%). All 
had demonstrated more than 15 obstructive or mixed (i.e. 
wholly or partly accompanied by persistent respiratory 
efforts) apnoea/hypopnoea episodes per hour of sleep on 
full-night polysomnography. 
Manual scores were recorded according to standard rules 
(5). All subjects were free of cardiac, respiratory, neuro- 
logic, hepatic or endocrine disease, except for one patient 
who had mild obstructive pulmonary disease, and none of 
the patients were dieting at the time of the study. Spirom- 
etry was performed according to American Thoracic 
Society recommendations using a spirometer (Gould 2800) 
(6). Arterial gasometry was recorded with an ABL 30 
gasometer (Copenhagen). 
The AH1 was defined as the mean number of hypopnoeic 
and apnoeic episodes per hour of sleep. Apnoeic episodes 
were defined as the absence of nasal and oral air flow for at 
least 10 s measured by thermistor, and the absence of 
ventilation (summation of chest and abdominal excursion) 
greater than 10 s measured by calibrated inductive plethys- 
mography. Hypopnoea was defined as an estimated 50% or 
more reduction in oronasal air flow, associated with at least 
a 4% decrease in oxygen saturation. Nadir of SaO, during 
sleep (SaO, min) was defined by minimum SaO, during 
sleep. 
All patients underwent a follow-up nCPAP study. The 
appropriate pressure level was established based on the 
disappearance of AHI. Each patient was fitted with a nasal 
mask for use with the Respironics Sleep-Easy System 
III (Respironics Inc, Monroeville, PA, U.S.A.). Home 
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TABLE 1. Anthropometric and spirometric values of 10 To compare the results obtained among the different 
obstructive sleep apnoea patients (nine male, one female) groups, the Friedman Anova test and the Wilcoxon paired 
before nasal continuous positive airway pressure (nCPAP) t-test were used. Differences were considered significant at 
treatment and after 2 years of nCPAP therapy P<O.O5. 
Before After 
Results 
BMI (kg m - ‘) 
Age (years) 
Height (cm) 
Weight (kg) 
FVC (1) 
FVC (%) 
FEV, (1) 
FEV, (%) 
FEVJFVC (%) 
33.25 (5.8) 33.64 (4.7) 
53.60 (7.3) 
167.60 (0.1) 167.50 (0.1) 
93.1 (12.8) 94.2 (10.5) 
3.79 (0.9) 3.66 (1.7) 
85.1 (10.5) 84.4 (10.2) 
2.96 (0.9) 2.83 (1.0) 
85.1 (15.6) 84.7 (13.8) 
78.10 (10.4) 77.30 (9.5) 
The anthropometric data and results of spirometry before 
treatment and 2 years later are given in Table 1. No 
significant differences were observed. 
All values are means f SD. 
Table 2 shows the sleep characteristics of OSA patients 
before nCPAP therapy and on the first night after 2 years of 
nCPAP treatment. (Treatment was withdrawn on nights 2 
through 5.) The patients hardly experienced deep sleep 
(stages 3 and 4), probably due to the severity of OSA in the 
sample studied (47 f 17 events h- ‘). Furthermore, the 
‘awake’ period is lengthened at the start of CPAP as a result 
of adaptation to the treatment. 
nCPAP therapy was continued for 2 years (720 i 30.6 
days). Average nightly use of nCPAP was 6.9 f 1.2 h per 
patient. 
Four check-ups per year were performed at the authors 
centre in order to ascertain whether the therapy was being 
properly followed or whether there was non-compliance. 
The mean nCPAP pressure of 9.30 l 3.09 cm H,O was 
not changed over the 2-year treatment period, except in the 
case of one patient for whom the pressure was increased by 
2 cm H,O. Nasal nCPAP compliance was good in all 
patients. 
The Friedman Anova test was significant for AH1 
@=28.98, P<O.O006); SaO, min k2=21.9, P<O.O012) and 
PaCO, &=21.89, P<O.OOlO). Comparison of baseline 
AH1 to AH1 2 years later by way of the Wilcoxon paired 
t-test showed that AH1 had decreased significantly with 
CPAP therapy (on the first night on nCPAP) after 2 years 
of treatment (P<O.O05, z=2.8) (Fig. 1). No clinically 
important long-term effects of nCPAP were observed when 
the patient was not being treated (Baseline and night 2 
columns in Table 2), and, moreover, there was no loss or 
decrease of effect of nCPAP even when treatment continued 
over 2 years (nCPAP columns on Table 2). 
Two years after the start of treatment, polysomnographic 
studies were again performed, this time over five consecu- 
tive nights. The usual nCPAP therapy was applied on 
the first night. Over the next 4 nights, no nCPAP was 
applied. 
The withdrawal of nCPAP produced, on the first night 
and without nCPAP, an immediate increase in AH1 to the 
pretreatment baseline level (P<O.Ol, z=2.54). SaO, min 
was higher than baseline on CPAP after 2 years of treat- 
ment (PcO.006, z=2.7) and decreased nearly to baseline 
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TABLE 2. Sleep and gasometric parameters of 10 obstructive sleep apnoea patients (nine male, one female) before and after 2 
years of nasal continuous positive airway pressure (nCPAP) therapy 
Pre-nCPAP therapy Post-nCPAP therapy 
Basal nCPAP 1 nCPAP 2 3 4 5 
TST (min) 379 (38) 370 (48) 234 (76.3) 288 (69.5) 312 (69.5) 304 (80.9) 310 (101) 
Awake (%) 26.8 (20) 34.5 (14) 28.0 (15) 20.2 (14) 12.9 (10) 15.8 (16) 17.6 (12) 
Stage 1 (%) 18.6 (13) 20.0 (9) 21.7 (10) 24.7 (10) 26.8 (14) 18.1 (7) 26.1 (19) 
Stage 2 (%) 50.0 (19) 36.0 (9) 45.2 (11) 56.2 (17) 56-O (19) 63.2 (20) 52.7 (16) 
Stages 3 & 4 (%) 0.1 (0.3) 1.8 (1) 0.2 (0.6) 0.1 0 
REM (%) 3.5 (4.2) 6.5 (7) 5.1 (5.6) 2.5 (3.7) 3.8’(3.5) 3.9O(4.1) 3.6 (3.2) 
SaO, min (%) 69.2 (11) 83.5 (7) 87.0 (7.2) 76.0 (12) 76.7 (12) 74.5 (12) 71.0 (17) 
AH1 (event s h - ‘) 47.0 (17) 5.4 (2) 5.3 (11.3) 40.5 (27) 44.1 (19) 42.2 (24) 35.8 (21) 
PH 7.41 (0.0) 7.40 (0.0) 7.41 (0.0) 7.40 (0.0) 7.40 (0.0) 7.39 (0.0) 7.41 (0.0) 
PaO, (mmHg) 72.2 (13) 83.7 (8.5) 82.8 (9.9) 79.1 (8.1) 80.3 (10) 78.0 (7) 78.0 (10) 
PaCO, (mmHg) 41.5 (9) 36.1 (2.3) 38.6 (3.5) 40.1 (2.9) 40.4 (3.3) 41.1 (2.7) 41.1 (3.2) 
All values are means f SD. 
Night 1 after nCPAP therapy was studied with nCPAP. Nights 2-5 were studied without nCPAP therapy. SaO, min, nadir 
of SaO, during sleep; SaO,, diurnal arterial oxygen saturation. 
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FIG. 1. Results of apnoea-hypopnoea index pre- and 
post-nasal continuous positive airway pressure (nCPAP) 
treatment. All values are means * SD. On, with nCPAP 
therapy; Off, nCPAP withdrawal. AH1 increased signifi- 
cantly at Night 2 (Off nCPAP) with respect to Night 1 
(On nCPAP). *PcO.O05; TP<O.Ol. 
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when nCPAP therapy was’withdrawn (PcO.007, z=2.8). 
The effect of withdrawing CPAP therapy on SaO, min was 
evident by the second night of the post-nCPAP treatment 
study. This change continued on the remaining nights (Fig. 
2). Without CPAP, PaCO, increased significantly on the 
fourth night of the post-CPAP study (PcO.037, z=2.1), 
reaching a level that was similar to that of the baseline 
study. 
Discussion 
The main finding of this study is that interruption of 
long-term nCPAP treatment in patients with OSA has 
negative sleep function consequences, as shown by the 
return of AHI values to levels that are similar to those 
displayed before treatment, on the first night without 
nCPAP after 2 years of treatment. Similarly, the SaO, min 
recordings decreased progressively throughout the days 
following nCPAP withdrawal. 
Nasal CPAP is an effective treatment for OSA (7), which 
generally produces a decrease in the number of nocturnal 
AHI incidents, and improves arterial blood gas levels after 
prolonged therapy (7-10). Although the positive effects of 
nCPAP use in patients with OSA are well known, the 
contrary effect is not, that is to say the effect of withdrawing 
nCPAP temporarily. The studies reported to date show 
conflicting results. Among the studies that show that 
nCPAP has a beneficial effect on the disease through 
continuous usage, the works of Kribbs (3) Leech (10) and 
Rauscher (4) stand out. In all three studies, AH1 decreases 
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FIG. 2. Results of nocturnal SaO, min pre- and post- 
nasal continuous positive airway pressure (nCPAP) treat- 
ment. All values are means + SD. On, with nCPAP 
therapy; Off, nCPAP suppression. With nCPAP suppres- 
sion, SaO, min decreased significantly. *P<O.O06; 
~P<O~OO7. 
after more or less prolonged treatment (ranging from 2 to 
12 months). The positive effect has been attributed to a 
decrease in upper airway oedema or to changes in venti- 
latory control. Increases in SaO, min are also produced. 
Not all the studies have shown positive effects, however. 
Collop et al. (9) studied 12 patients treated over 6 weeks 
with nCPAP, and observed that the AHI index does not 
decrease below baseline when nCPAP is withdrawn tempor- 
arily (4X.4 to 44.5 events per h) although in the most severe 
patients (AHI> events per h), a decrease in AHI (87 to 61 
events per h) was observed. No changes in pharynx volume 
measured through magnetic resonance were observed. The 
effect of withdrawing nCPAP for more than a single night is 
also unknown. 
In this 5-day study of 10 OSA patients after 2 years of 
treatment with nCPAP, treatment was withdrawn from the 
second night of study to the fifth night. The AH1 increased 
on the very first night without nCPAP. These results thus 
extend those of Collop et al. (9) showing that the effect of 
nCPAP withdrawal continues beyond the first night. With- 
drawal of nCPAP led to an AH1 level similar to that 
recorded before treatment. Consequently, suppression of 
nCPAP therapy for 1 night, as in intermittent nCPAP 
therapy, is likely to leave patients in a situation comparable 
to receiving no benefit. 
Furthermore, interrupting nCPAP treatment affects gas 
exchange, as shown by the present finding of a decrease in 
SaO, min (87.0 & 7.2 to 71.0 & 0 & 7%) over the 5 nights 
studied, the last value being near to that recorded before 
treatment (69.2 f 11% to 71.0 i 17%). PaO, had a tendency 
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to decrease, though not significantly, over the 5 nights. An 
increase in PaCO, observed after the first night became 
significant on the fifth night. This deleterious effect of 
nCPAP interruption has not been observed previously. 
Other systemic effects can be expected, although they 
remain to be studied. Arterial pressure and heart rate; 
which are known to decrease with nCPAP to a greater 
degree for those who are hypertensive (11,12), may also 
increase to baseline levels when CPAP is interrupted, thus 
increasing cardiovascular risk. 
In conclusion, interruption of nCPAP therapy in OSA 
patients treated long-term (2 years in this case) increases 
AH1 and is detrimental to gasometric parameters. Inter- 
rupting nCPAP therapy for more than 1 night results in 
respiratory disturbances in patients with OSA as variables 
return to levels similar to those found before nCPAP 
treatment. It therefore appears that alternative ways of 
delivering nCPAP, such as on alternate days or with 
weekends off, are contraindicated, and furthermore that 
there is no effect of addiction of nCPAP that would 
contraindicate its long-term use. Any changes in the proto- 
col applied to prescribe nCPAP therapy must be checked 
for negative effects. 
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